

Hepatitis C Coinfection

This is a PDF version of the following document:

Module 4: [Co-Occurring Conditions](#)

Lesson 6: [Hepatitis C Coinfection](#)

You can always find the most up-to-date version of this document at

<https://www.hiv.uw.edu/go/co-occurring-conditions/hepc-coinfection/core-concept/all>.

Background and Epidemiology

General Hepatitis C Epidemiology

Hepatitis C virus (HCV) is a single-stranded RNA virus that is an important cause of cirrhosis, liver failure, and hepatocellular carcinoma. Globally, an estimated 130-150 million people are living with HCV.[1] In the United States, the most recent prevalence data from a National Health and Nutrition Examination Survey (NHANES) estimated 2.4 million persons were HCV RNA positive and 4.1 million were HCV antibody positive.[2] The Centers for Disease Control and Prevention (CDC) estimate that at least two-thirds of all persons with active HCV in the United States were born between 1945 and 1965.[3] Since 2002, however, the number of new HCV cases among younger persons has increased significantly, leading to a bimodal distribution, with peaks at 29 and 59 years of age.[4,5,6] Although the annual number of contemporary new HCV infections in the United States is markedly lower than in the 1980s, the incidence increased significantly from 2010 through 2020 (Figure 1).[6,7] Indeed, compared with 2013, the incidence rate of acute HCV has doubled. The greatest relative increases occurred among adults 20 to 39 years of age, and the burgeoning acute HCV infection rates in the United States in recent years correlate directly with the ongoing major opioid epidemic.[6]

Epidemiology of HIV and HCV Coinfection

In the United States, approximately 15 to 30% of persons with HIV have HCV coinfection.[5,8] The prevalence varies according to the risk factor for HIV and HCV acquisition, with the highest rates among persons with HIV who inject drugs and individuals with hemophilia who were infected through receipt of blood products prior to routine screening of blood products for HCV.[9,10,11] Since 2000, in the United States, Europe, Asia, and Australia, HCV infection has emerged as an important sexually transmitted infection among men with HIV who have sex with men.[12,13,14,15,16] Researchers have identified several risk factors associated with the sexual acquisition of HCV in persons with HIV, including non-injection recreational drug use, condomless receptive anal intercourse, use of sex toys, concurrent sexually transmitted infections (STIs), anal douching, and low CD4 cell count.[17,18,19]

Transmission of HCV

The most efficient route of transmission of HCV is through percutaneous exposure to blood or blood products (e.g., via sharing of injection drug equipment, blood transfusion, or organ transplantation), but HCV is also transmitted through sexual contact (especially with condomless receptive anal intercourse), perinatally from mothers to infants, and rarely through environmental exposures.

General Approach to Persons with HIV and HCV Coinfection

With increasing data showing a number of direct-acting antiviral (DAA) agents are highly effective and safe for the treatment of HCV in persons with HIV, all persons with HIV and HCV coinfection should be evaluated for treatment of HCV. Rates of HCV cure with DAA-based therapy have uniformly exceeded 95%, and experts now consider the approach to treatment of HCV in persons with HIV coinfection similar to that in persons with HCV mono-infection, except for needing to consider drug interactions between DAAs and antiretroviral medications.[\[20,21\]](#) A proactive and aggressive approach to HCV is needed in persons with HIV—identify and treat HCV in all persons with HIV and HCV coinfection. This strategy would lead to improved health outcomes and longer survival in persons with HIV, as well as reduced transmission of HCV.[\[22\]](#)

Natural History of HIV-HCV Coinfection

Impact of HIV on the Natural History of HCV Infection

In persons with HCV monoinfection, approximately 20% will spontaneously clear HCV. Preexisting HIV decreases the likelihood of spontaneous HCV clearance to approximately 5 to 15%.[\[23,24\]](#) Compared with individuals who have HCV monoinfection, persons with HIV and HCV coinfection have accelerated rates of liver fibrosis and a more aggressive course of liver disease ([Figure 2](#)).[\[5,25,26\]](#) Progression to cirrhosis occurs 12 to 16 years earlier in persons with HIV and HCV coinfection compared with persons who have HCV monoinfection.[\[27,28\]](#) The accelerated liver disease seen in persons with HIV and HCV coinfection is generally more pronounced when HIV infection precedes HCV infection.[\[28\]](#) In persons with HIV-HCV coinfection, more rapid liver fibrosis progression rates have been associated with low CD4 count, higher alcohol consumption rate, and younger age.[\[26\]](#) Compared with persons who have HCV monoinfection, those with HIV-HCV coinfection typically develop hepatocellular carcinoma at a younger age and have more aggressive tumors.[\[26,29,30\]](#) The use of effective antiretroviral therapy does not appear to fully neutralize the adverse effect of HIV on the progression of HCV-related liver disease.[\[31,32\]](#)

Impact of HCV Infection on the Natural History of HIV

Most studies have reported that HCV does not significantly impact HIV disease progression.[\[33,34,35\]](#) Some studies have shown that coinfection with HCV may blunt increases in CD4 cell counts after initiation of antiretroviral therapy, whereas others have shown no significant impact of HCV on immune reconstitution.[\[34,35,36\]](#) Achieving a sustained virologic response (SVR) with HCV treatment has not been shown to impact CD4 count or percentage.[\[37\]](#) Chronic HCV infection increases the risk of hepatotoxicity due to antiretroviral therapy in persons with HIV.[\[38,39\]](#) Nevertheless, for nearly all individuals with HIV and HCV coinfection, including those with cirrhosis, the benefits of antiretroviral therapy outweigh the risks of liver injury caused by antiretroviral medications, particularly with use of currently recommended antiretroviral regimens in the United States, which rarely are associated with hepatotoxicity when compared to older antiretroviral regimens.[\[40,41\]](#)

Hepatitis C-related Deaths in Persons with HIV

Multiple cohort studies have identified shifting patterns of mortality for individuals with HIV as they are living longer with effective antiretroviral therapy. Liver disease, especially due to chronic infection with hepatitis B virus (HBV) or HCV, is now a leading cause of mortality among persons with HIV.[\[42\]](#) Although HIV-related mortality has decreased with the availability of antiretroviral therapy, several large cohort studies in Europe have demonstrated that persons with HIV-HCV coinfection have higher rates of liver-related death compared to persons with HCV monoinfection.[\[43,44,45,46\]](#) In the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort study, analysis of 1,246 deaths in persons with HIV during the years 1999 through 2004 found that 14.5% resulted from liver causes and HCV infection was a predictor of liver-related death ([Figure 3](#)).[\[46\]](#) In the follow-up D:A:D cohort study from 1999 through 2011 that included 308,719 person-years of data, the percentage of deaths due to liver disease had decreased over time, but liver disease remained the third leading cause of death (13%) behind AIDS-related causes and non-AIDS-related malignancies.[\[47\]](#)

Screening for HCV Infection

Screening for HCV in Persons with HIV

As recommended in the Adult and Adolescent OI Guidelines, all persons with HIV should undergo routine testing for HCV infection at entry to care, primarily because of the high rate of HCV coinfection among persons with HIV.[\[4\]](#)

Repeat Screening for HCV Infection

Individuals with HIV who are at risk of acquiring HCV, including persons who inject drugs, men who have sex with men, and transgender women, should have annual HCV antibody testing, or more frequently, if indicated based on exposure to HCV.[\[4,48\]](#) Reinfection with HCV can occur in individuals who achieve an SVR with HCV therapy, as underscored by recent reports showing significant rates of HCV reinfection among men with HIV who have sex with men.[\[49\]](#) Because HCV antibody remains reactive after successful HCV therapy, follow-up HCV antibody testing will not be able to identify new HCV infection in persons previously cured of HCV infection. In this situation, an HCV RNA test should be used to screen for reinfection, at least annually, if indicated based on risk.[\[50\]](#)

HCV Diagnostic Testing

Recommended HCV Diagnostic Testing Sequence

In May 2013, the Centers for Disease Control and Prevention published a recommended testing sequence for diagnosing current (active) HCV infection ([Figure 4](#)).[\[51\]](#) The recommended sequence consists of initial testing for HCV antibody (using either a rapid or laboratory-conducted assay), followed by HCV RNA testing for all people who have a positive HCV antibody test.[\[51\]](#) Many laboratories now have a protocol to reflexively perform HCV RNA testing on all positive HCV antibody tests using the same blood sample. Note the diagnostic testing sequence recommended by the CDC is not intended for diagnosing acute HCV infection.[\[51\]](#)

Antibody Tests

Initial testing for the diagnosis of HCV infection utilizes serologic assays that detect human antibodies generated as a response to HCV infection. A positive antibody test indicates infection at some point in time, but it does not differentiate whether the person has resolved HCV infection or chronic (active) HCV infection. Several types of antibody tests are available.[\[48,52\]](#):

- **Enzyme Immunoassay (EIA):** In the United States, the third-generation EIA test is the preferred serologic assay to use as the initial diagnostic test for HCV infection. The third-generation EIA detects antibodies that bind to recombinant antigens derived from multiple viral regions.[\[53,54\]](#) The EIA test is reported as positive or negative based on an absorbance signal compared with a cutoff value. The third-generation EIA has a sensitivity of approximately 98%. The EIA has a reported specificity of greater than 99%, with false-positive tests occurring more frequently in populations that have a very low HCV prevalence.
- **Chemiluminescence Immunoassay (CIA):** The CIA test is an antibody test similar to the EIA. The CIA is used less frequently than the EIA test. The CIA has similar sensitivity and specificity as the third-generation EIA.
- **Point-of-Care Rapid Immunoassays:** The OraQuick HCV rapid screening antibody test was approved by the FDA in 2010 for use with whole blood samples obtained either by venipuncture or fingerstick (despite the brand name of the test, it is not intended for use on oral samples). The test is read between 20 and 40 minutes after the test device is inserted into the buffer, and the result is either reactive or nonreactive. The specificity and sensitivity of the OraQuick HCV test are similar to laboratory-based HCV antibody assays.[\[48,55\]](#) An individual with a reactive test should be considered to have a preliminary positive test and should undergo supplemental HCV testing.

Molecular HCV RNA Tests

Molecular diagnostic tests for HCV specifically detect HCV RNA and are commonly referred to as a nucleic acid test (NAT) or nucleic acid amplification test (NAAT).[\[52\]](#) The HCV NAT becomes positive approximately 1 to 2 weeks after acquiring HCV. Low HCV RNA levels may be intermittently detectable very early after infection.[\[56,57\]](#) The NAT test has become the gold standard supplemental test following a positive HCV antibody screening test. The NAT can usually determine whether a person with a positive HCV antibody test has chronic HCV or resolved HCV infection. In addition, the NAT can be used to diagnose individuals with acute HCV infection, but unlike with acute HIV, the HCV RNA test can be negative or barely detectable with acute HCV infection. In a clinical scenario where HCV RNA is negative but acute HCV is highly suspected, it is advisable to repeat the HCV RNA test several months later.

- **Quantitative HCV RNA:** The quantitative HCV RNA test is the preferred HCV supplemental test and can determine whether an individual has chronic infection. The ultrasensitive HCV quantitative RNA assays, which detect as few as 5 copies/mL, provide the same level of diagnostic accuracy as the qualitative assay. In addition, if a quantitative HCV RNA assay is used for diagnostic purposes, positive results will include an HCV RNA quantitative value, which provides useful information as a baseline

and pretreatment HCV RNA level. The results for the commercially available HCV RNA assay are given in International Units (IUs).

- **Qualitative HCV RNA:** The qualitative HCV RNA test provides a “yes” or “no” answer to whether detectable HCV RNA is present in the sample. It does not provide a quantitative level of HCV. Because the sensitivity of the quantitative HCV RNA assay has dramatically improved in recent years, the utility of the qualitative HCV RNA has markedly diminished, and it is infrequently used.

Interpretation of Test Results

Individuals who have a negative screening HCV antibody test result are considered not infected with HCV, unless a false-negative test result is suspected. Studies have demonstrated false-negative HCV test rates of up to 3.2% in persons with HIV, with most of the false-negative results occurring in persons who have a CD4 count of less than 200 cells/mm³.[\[58\]](#) Thus, if an individual is at high risk for HCV infection, HCV RNA testing should be considered if the HCV antibody test is negative. As previously noted, HCV antibody tests can also be falsely negative in the “window period” of acute HCV infection before the production of anti-HCV antibodies. The HCV window period ranges from 2 to 12 weeks, so HCV RNA testing is helpful during this period, especially in persons who have elevated alanine aminotransferase (ALT) levels that suggest acute HCV infection.[\[4\]](#) Persons with a positive HCV antibody test and a positive HCV RNA assay are considered to have current (active) HCV infection. Individuals who have a positive HCV antibody test and a negative HCV RNA test are considered to have no evidence of current HCV infection. Note that the 2013 HCV diagnostic testing sequence recommended by the CDC is not intended for diagnosing acute HCV.[\[51\]](#)

Evaluation of Persons Diagnosed with HCV Coinfection

Due to the rapidly changing landscape of HCV treatment, the AASLD-IDSA HCV Guidance is regularly updated.[48] A comprehensive evaluation of persons with HIV who are diagnosed with HCV coinfection should include routine laboratory evaluation, HCV-specific tests, status of hepatitis A and B, and assessment of liver fibrosis. The newer simplified treatment approach in the AASLD-IDSA HCV Guidance recommends using a pangenotypic DAA-based regimen, and this new approach streamlines the baseline laboratory evaluation.[48]

Routine Laboratory Evaluation

With the simplified treatment approach, all individuals diagnosed with HCV should have a complete blood count (CBC) with differential, comprehensive metabolic panel (CMP) that includes assessment of renal function (creatinine, estimated glomerular filtration rate [GFR]) and hepatic function (ALT, aspartate aminotransferase [AST], total and direct bilirubin, and albumin).

HCV-Specific Tests

All persons with chronic HCV should have quantitative HCV RNA testing (if not done at the time of HCV diagnosis).[40] The quantitative HCV RNA level provides documentation of chronic HCV infection but does not correlate with the degree of liver inflammation or fibrosis.[59,60] With the simplified treatment approach of using a pangenotypic regimen, ordering an HCV genotype is not recommended. Although the HCV genotype has become less relevant with the simplified approach of using pangenotypic DAAs, it may be indicated in three situations: (1) if required by an insurance company for medication approval; (2) if an individual has cirrhosis and sofosbuvir-velpatasvir is the planned treatment regimen; and (3) an individual does not meet criteria for simplified HCV treatment.

Hepatitis A and Hepatitis B Status and Immunization

For persons with chronic HCV infection, superinfection with hepatitis A virus (HAV) can cause fulminant hepatitis.[61] Thus, all persons with chronic HCV infection should be assessed for immunity to HAV with total hepatitis A antibody and evaluated for HBV with hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc).[48] The recommendation to screen for hepatitis A and B also applies to all people with HIV. Individuals without immunity to HAV should receive hepatitis A immunization. Similarly, those without immunity to HBV should be vaccinated against HBV.[4] Awareness of hepatitis B status in persons with chronic HCV has taken on increased importance with recent reports of HBV reactivation and hepatitis flares during treatment of HCV with direct-acting antiviral agents.[40,62,63]

Assessment of Stage of Liver Fibrosis

Individuals with chronic HCV should be assessed for the presence of advanced fibrosis using noninvasive methods to help with treatment decisions and to determine the need for screening for hepatocellular carcinoma. Fibrosis is the most robust predictor of liver-related clinical outcomes in persons with chronic HCV, and a more rapid progression of hepatic fibrosis occurs in persons with HIV-HCV coinfection.[27,31] A liver biopsy is no longer recommended for liver fibrosis staging in HIV and HCV coinfection, unless there are other clinical indications to obtain one.[4] Regardless, limited or no access to additional staging modalities should not preclude HCV treatment.[4]

- **Noninvasive Test to Assess Hepatic Fibrosis:** The Adult and Adolescent OI Guidelines recommend using the FIB-4 blood test for fibrosis staging ([FIB-4 Calculator](#)).[4] A FIB-4 score less than 1.45 has a negative predictive value of 90% for advanced fibrosis.[64] In contrast, a FIB-4 greater than 3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis.[64] For individuals with an indeterminate FIB-4 (1.45–3.25) score, noninvasive imaging modalities such as transient elastography or magnetic resonance elastography may be indicated, especially if there are

any other clinical or laboratory findings that suggest cirrhosis.[4]

Evaluation of Alcohol Use

Numerous studies have found a strong association between the use of alcohol and the development (or progression) of liver fibrosis and hepatocellular carcinoma.[65,66,67] Some studies have demonstrated that the risk of developing cirrhosis and decompensated liver disease in persons with chronic HCV infection is 2- to 3-fold higher for individuals with significant alcohol intake compared with those who have minimal or no alcohol intake.[68] The threshold level above which alcohol potentiates the progression of HCV disease is unknown, but it appears that even moderate levels of alcohol consumption accelerate histological lesions in persons with chronic HCV infection.[67] Individuals who are identified as having an alcohol use disorder or dependence should be referred to an addiction specialist and/or treatment program, but this should not preclude initiating HCV treatment.[48]

Assessment of Acetaminophen and Iron Intake

Persons with HIV and HCV coinfection should also be counseled to limit ingestion of acetaminophen to less than 2 grams per day and avoid iron supplementation in the absence of documented iron deficiency.[4]

Education to Avoid HCV Transmission to Others

Transmission of HCV primarily occurs via infected blood and persons with HCV infection should receive counseling on how to prevent transmission of HCV to others.[48,69,70,71] In general, the prevention measures are similar to those used to reduce HIV transmission (since HIV and HCV share the same routes of transmission). People who inject drugs should be encouraged to stop their drug use; if they are unable to stop use of injection drugs, they should be counseled to never share injection equipment.[4] Use of condoms should be emphasized in men who have sex with men since sexual transmission of HCV has been increasingly reported in this group. In addition, persons with HCV should avoid sharing any devices that may be contaminated with blood, such as razors or toothbrushes. The prevention of perinatal transmission of HCV is discussed later in this topic review.

Treatment of HIV in Persons with HCV Coinfection

The Adult and Adolescent ART Guidelines recommend initiating HIV antiretroviral therapy in all persons with HIV (regardless of CD4 cell count), including all persons with HIV and HCV coinfection.[\[40,72\]](#) Ideally, initiation of antiretroviral therapy should occur before HCV treatment and after suppression of HIV RNA levels, which typically takes less than 3 to 4 months. The choice of the initial HIV antiretroviral therapy regimen should take into account potential drug interactions with the anticipated direct-acting antiviral agents to be used for HCV treatment. In general, the use of unboosted integrase strand transfer inhibitor (INSTI)-based HIV antiretroviral therapy allows for concomitant treatment of HCV without major concerns for drug interactions. The use of tenofovir alafenamide, which has an improved safety profile when compared with tenofovir DF, has also minimized concerns about combined antiretroviral and DAA medication toxicity.[\[40\]](#) For these reasons, persons anticipating DAA treatment of HCV should ideally receive either an antiretroviral regimen that includes an unboosted INSTI but avoids tenofovir DF (e.g., bictegravir-tenofovir alafenamide-emtricitabine or dolutegravir plus tenofovir alafenamide-emtricitabine). Antiretroviral medications may require dose adjustment or may be contraindicated with liver cirrhosis. No dosage adjustment of bictegravir-tenofovir alafenamide-emtricitabine or dolutegravir plus tenofovir alafenamide-emtricitabine is recommended for individuals with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, but these regimens are not recommended for use with severe hepatic impairment (Child-Pugh Class C). In addition, since HBV reactivation can occur during HCV treatment with DAAs, it is important that the HIV antiretroviral regimen includes agents with activity against HBV if indicated.

Treatment of HCV in Persons with HIV Coinfection

Rationale for Treatment

The long-term goal of treatment of HCV infection is to reduce liver-related morbidity and all-cause mortality through the achievement of virologic cure.[\[48,73\]](#) Multiple studies have shown treatment of HCV in persons with HIV is highly successful, with SVR12 rates typically exceeding 95%.[\[74,75,76\]](#) Treatment of HCV is now recommended for all individuals with HIV and HCV coinfection.[\[4,20,77\]](#)

Goals of HCV Therapy

The short-term goal of HCV therapy in persons with HCV and HIV coinfection is to achieve an undetectable HCV RNA level 12 weeks after completion of HCV therapy, a goal commonly referred to as a sustained virologic response at posttreatment week 12 (SVR12) ([Figure 5](#)). Among persons who attain an SVR12, more than 99% will maintain the SVR years after completion of therapy and thus are deemed to have a virologic cure of hepatitis C infection.[\[78\]](#) Overall long-term health outcome goals with HCV treatment include reduced risk for hepatocellular carcinoma and lower liver-related mortality.[\[79,80\]](#)

Simplified HCV Treatment Approach

Many DAAs are now available for treatment of HCV, and most are safe, highly effective, and convenient.[\[20,21\]](#) Numerous studies with all-oral DAA regimens have demonstrated comparable sustained virologic response (SVR) rates when treating persons with HIV and HCV coinfection as with those who have HCV mono-infection.[\[37,81,82,83,84\]](#) The excellent safety and high efficacy of pangenotypic DAAs (glecaprevir-pibrentasvir and sofosbuvir-velpatasvir) have greatly streamlined the HCV treatment process.[\[74,85,86,87\]](#) The AASLD-IDSA HCV Guidance now includes recommendations for a simplified HCV treatment approach that applies to most people with chronic HCV, including people with HIV coinfection.[\[4,88\]](#) The following will address the four main components of the simplified HCV treatment approach in persons with HIV: (1) criteria for the simplified HCV treatment approach, (2) baseline evaluation, (3) pangenotypic regimen options, and (4) treatment-related monitoring.[\[4,88\]](#)

Criteria for Simplified HCV Treatment Approach in People with HIV

The simplified HCV treatment approach can be used for most people with HIV. The simplified treatment regimens apply to both chronic HCV and acute HCV.[\[4\]](#) The following is a list of exclusions for the simplified HCV treatment approach in persons with HIV.[\[4\]](#)

- Prior HCV treatment (reinfection after prior successful therapy is not an exclusion)
- Decompensated cirrhosis (including, but not limited to, current or prior variceal bleeding, ascites, or hepatic encephalopathy)
- Tenofovir DF-containing regimen with an eGFR less than 60 mL/min
- On an antiretroviral regimen that includes efavirenz, etravirine, nevirapine, or boosted HIV-1 protease inhibitors
- Untreated chronic HBV infection
- Pregnancy

Baseline evaluation with Simplified HCV Treatment Approach in People with HIV

The initial evaluation of persons diagnosed with HCV was outlined in detail in the section Evaluation of Persons Diagnosed with HCV Coinfection. The following list summarizes the recommended evaluation for persons who are candidates for the simplified HCV treatment approach.^[4]

- Complete blood count (including platelet count)
- Liver function tests
- Serum creatinine
- HCV RNA
- Hepatitis B surface antigen
- Initial fibrosis staging using FIB-4 ([FIB-4 calculator](#))
- Review of concomitant medications and drug interactions
- HCV genotype (if cirrhosis is present)

Simplified HCV Treatment Regimens in People with HIV

In persons with HIV and chronic HCV infection, who meet the simplified treatment criteria outlined above, the Adult and Adolescent OI Guidelines recommend using either of the following pangenotypic DAA regimens, based on whether the person has or has not compensated cirrhosis.^[4]

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Simplified HCV Treatment Regimens in People with HIV*

Treatment-Naïve Patients Without Cirrhosis (Any Genotype or No Pretreatment Genotype)
<ul style="list-style-type: none">• Glecaprevir-pibrentasvir (Mavycont®): three tablets daily for 8 weeks (AI), or• Sofosbuvir-velpatasvir (Vosevi®): one tablet daily for 12 weeks (AI)
Treatment-Naïve

Patients with Compensated Cirrhosis (Recommendations Based on HCV Genotype)
HCV Genotypes 1, 2, 4, 6
<u>Preferred Therapy</u> <ul style="list-style-type: none">Glecaprevir-pibrentasvir: three tablets daily for 8 weeks (AIII), orSofosbuvir-velpatasvir: one tablet daily for 12 weeks (AI)
<u>Alternative Therapy</u> <ul style="list-style-type: none">Glecaprevir-pibrentasvir: three tablets daily for 12 weeks (CI)
HCV Genotype

3
<p><u>Preferred Therapy</u></p> <ul style="list-style-type: none">• Glecaprevir-pibrentavir (AIII) <p>: three tablets daily for 8 weeks</p>
<p><u>Alternative Therapy</u></p> <ul style="list-style-type: none">• Glecaprevir-pibrentavir <p>: three tablets daily for 12 weeks</p> <p>, or</p> <ul style="list-style-type: none">• Sofosbuvir-velpatasvir tablet: one daily, with or without ribavirin for 12 weeks pending results of NS5A resistance testing

**Treatment of
Acute HCV
Infection**

- Glecaprevir-pibrentasvir:
three tablets daily for 8 weeks (AII), or
- Sofosbuvir-velpatasvir:
one tablet daily for 12 weeks (AII)

*Each glecaprevir-pibrentasvir tablet contains glecaprevir (100 mg) and pibrentasvir (40 mg); each sofosbuvir-velpatasvir tablet contains sofosbuvir (400 mg) and velpatasvir (100 mg)

Recommendations for treatment after DAA failure are not provided; see the corresponding section in AASLD/IDSA HCV Treatment

- Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Hepatitis C virus. Last Updated: January 18, 2023 [[HIV.gov](https://www.hiv.gov)]

Treatment of HCV in Persons without Cirrhosis (Any Genotype or No Pretreatment Genotype)

- **Glecaprevir-pibrentasvir:** This is a fixed-dose combination regimen (glecaprevir 100 mg and pibrentasvir 40 mg); three tablets should be taken once daily with food for 8 weeks.
- **Sofosbuvir-velpatasvir:** This is a fixed-dose combination regimen (400 mg sofosbuvir and 100 mg velpatasvir); one tablet should be taken once daily with or without food for 12 weeks.

Treatment of HCV in Persons with Compensated Cirrhosis (Recommendations Based on Genotypes)

- **Glecaprevir-pibrentasvir:** This is a fixed-dose combination regimen (glecaprevir 100 mg and pibrentasvir 40 mg); three tablets should be taken once daily with food for 8 weeks. Note that some experts recommend extending this treatment to 12 weeks in persons with compensated cirrhosis.
- **Sofosbuvir-velpatasvir:** This is a fixed-dose combination regimen (400 mg sofosbuvir and 100 mg velpatasvir). Genotype information is needed in order to determine the exact therapy when this treatment is used in persons with compensated cirrhosis.
 - **Genotypes 1, 2, 4-6:** This is a fixed-dose combination regimen (400 mg sofosbuvir and 100 mg velpatasvir); one tablet should be taken once daily with or without food for 12 weeks.
 - **Genotype 3:** This is a fixed dose combination regimen; one tablet should be taken once daily for 12 weeks, with or without ribavirin for 12 weeks pending results of NS5A resistance testing (ribavirin should be used if the individual has HCV genotype 3 and a Y93H mutation).

Laboratory Monitoring and PostTreatment Follow-up

With the simplified HCV treatment approach, no laboratory monitoring is required during treatment.^[4] Note that some insurance companies and agencies require HCV RNA testing at week 4 of treatment to document an initial response in order to receive the additional refills needed to complete therapy.^[4] All persons receiving HCV treatment should have a quantitative HCV RNA level at baseline and at least 12 weeks after completing therapy ([Figure 6](#)).^[4] An undetectable HCV RNA level 12 weeks after completing therapy is referred to as SVR12 and indicates clearance and cure of HCV infection. Nevertheless, individuals who have successfully achieved an SVR12 do not have HCV immunity and thus are at risk of reinfection with HCV. Accordingly, patients should receive counseling regarding the potential for reinfection, and efforts should be made to engage individuals who have risk of reinfection in risk-reduction strategies, such as the use of syringe exchange services and medication-assisted therapy for people with opioid use disorder. Furthermore, screening for HCV reinfection with HCV RNA should be done at least annually for individuals who have ongoing risk factors for reinfection or more frequently based on clinical circumstances. As outlined in the following section, persons who met criteria for hepatocellular carcinoma screening should continue to have every 6-month screening.

Treatment of HCV in Persons who are Not Eligible for Simplified HCV Treatment

For persons with HIV who are not eligible for the simplified treatment approach, expert consultation is

recommended. In addition, data on retreatment of HCV in persons with HIV is very limited. More advanced expanded treatment recommendations are available in the AASLD-IDSA HCV Guidance.[20,89,90] In general, for those individuals who do not meet simplified treatment criteria, the choice of regimen and duration of therapy is based on cirrhosis status, HCV genotype, prior treatment regimen, and in some instances, HCV resistance testing.[20,89,90]

HCV Treatment Data in Persons with HIV Coinfection

The following information summarizes key phase 3 studies involving DAA-based therapy for HCV in persons with HIV coinfection.

- **Glecaprevir-Pibrentasvir (EXPEDITION-2):** This open-label, dual-arm, phase 3 trial examined the efficacy of glecaprevir-pibrentasvir in adults with HCV genotype 1, 2, 3, 4, 5, or 6 and HIV coinfection.[74] The 137 participants without cirrhosis received 8 weeks of glecaprevir-pibrentasvir, and the 16 with compensated cirrhosis received 12 weeks of glecaprevir-pibrentasvir.[74] Most (63%) of the participants had HCV genotype 1 infection; 19% were treatment experienced. All but 10 of the participants were taking either raltegravir, dolutegravir, or rilpivirine as the HIV antiretroviral therapy anchor drug. The overall SVR12 rate was 98%; one person with HCV genotype 3 and cirrhosis had an on-treatment virologic breakthrough.[74]
- **Sofosbuvir-Velpatasvir (ASTRAL-5):** The ASTRAL-5 study was a single-arm, open-label, phase 3 trial of treatment of HCV with sofosbuvir-velpatasvir for 12 weeks in adults with HIV-HCV coinfection.[91] The study enrolled 106 participants with HCV genotype 1, 2, 3, 4, or 6. Eighteen percent had compensated cirrhosis, and 29% were treatment experienced. The mean CD4 count was 583 cells/mm³, and all participants had suppressed HIV RNA levels. A variety of antiretroviral regimens, including tenofovir DF and pharmacokinetic boosting agents (cobicistat or ritonavir), were permitted. The overall SVR12 rate was 95%; two viral relapses occurred, both in the genotype 1a subgroup. The presence of cirrhosis or treatment experience did not appear to influence treatment response. Creatinine clearance was lower among those taking a boosting agent and tenofovir DF, but it remained relatively stable over time in all groups.[91]

Monitoring and Management of Chronic Liver Disease

Ongoing monitoring of liver disease is recommended for individuals in whom HCV therapy is deferred and posttreatment in persons with cirrhosis.[48,50] In persons with HIV and HCV coinfection in whom HCV treatment is deferred, routine monitoring should include laboratory assessment of hepatic function every 3 to 6 months; annual evaluation is appropriate to reevaluate hepatic fibrosis stage and to discuss modifiable risk factors for fibrosis (e.g., alcohol use) with more frequent evaluations for those with advanced liver disease.[20,48,50]

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

All persons with chronic HCV should have a body mass index (BMI) calculated since obesity is associated with accelerated progression of HCV-related fibrosis, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and insulin resistance.[92,93,94,95] The prevalence of MASLD among persons with HIV and HCV coinfection in cross-sectional studies has ranged from 30 to 70%.[96] Individuals with HCV infection who have MASLD, hyperlipidemia, or other cardiovascular comorbidities should also be considered candidates for lipid-lowering therapy, ideally with a statin medication. Prospective studies have demonstrated increased cardiovascular morbidity in persons with chronic liver disease, and statins have been shown to be safe and effective in persons with chronic HCV and other chronic liver diseases.[97,98]

Management of Persons with Cirrhosis

Individuals with HIV and HCV coinfection who have cirrhosis are at risk for severe complications related to their liver disease. The incidence rate of hepatocellular carcinoma (HCC) is 2 to 8% per year in persons with HCV-related cirrhosis; in persons with HIV and HCV coinfection, the HCC rates appear to be even higher, especially among patients with low CD4 counts.[99,100] These complications require special monitoring, including surveillance for hepatocellular carcinoma, evaluation for gastroesophageal varices, and consideration of liver transplantation for those with decompensated cirrhosis. Patients with advanced liver disease should be co-managed with practitioners with hepatology expertise.

- **HCC Surveillance Recommendations:** The 2023 AASLD HCC Guidance recommend hepatocellular carcinoma surveillance for all persons with chronic HCV who have cirrhosis, ideally using an abdominal ultrasound and serum alpha-fetoprotein approximately every 6 months.[101] For individuals with HCV infection and cirrhosis who have spontaneous or treatment-related clearance of HCV, the risk of developing HCC declines over time, but the risk reduction is not immediate. Therefore, these individuals should continue to receive HCC surveillance every 6 months.[50,101]
- **Screening for Gastroesophageal Varices:** Persons with HCV and cirrhosis should undergo screening with an esophagogastroduodenoscopy (EGD) to determine whether they have gastroesophageal varices large enough to warrant variceal bleed prophylactic therapy.[102] Individuals with varices should undergo evaluation by a medical provider or specialist experienced with management of cirrhosis and prevention of variceal bleeding. If no substantial varices are observed, then EGD should be repeated every 2 years, or sooner if liver decompensation occurs (progression from Child-Turcotte-Pugh Class A to Child-Turcotte-Pugh Class B/C cirrhosis).

Special Considerations During Pregnancy

Risk of Perinatal HCV Transmission

In pregnant people with HCV monoinfection, the risk of perinatal HCV transmission is 4 to 7%, and coinfection with HIV increases the risk of perinatal HCV transmission to approximately 10 to 14%.[\[4,10,103,104,105\]](#) Maternal HIV and HCV coinfection may also increase the risk of perinatal HIV transmission. As with HIV (and HBV), the risk of perinatal transmission of hepatitis C during pregnancy is correlated with higher HCV RNA levels, particularly near the time of delivery. Intrapartum HCV transmission is more common than in utero transmission.[\[104\]](#)

Management of HCV in Pregnant People who Have HIV Coinfection

Expert consultation is recommended for the management of pregnant people with HCV who have HIV coinfection. Current recommended DAA treatments for HCV have limited data for use in pregnancy. Note that ribavirin is absolutely contraindicated for use during any time of pregnancy. Effective combination antiretroviral therapy with at least three drugs is recommended to treat HIV for all pregnant people with HIV and HCV coinfection, regardless of CD4 cell count or HIV RNA levels.[\[106\]](#) Suppressive antiretroviral therapy for pregnant persons, which markedly lowers the risk of perinatal HIV transmission, may also reduce the risk of perinatal HCV transmission.[\[106,107\]](#)

- **AASLD-IDSA Recommendations:** The AASLD-IDSA HCV Guidance indicates that treatment for hepatitis C with DAAs can be considered during pregnancy on an individual basis after shared decision-making regarding the potential risks and benefits.[\[108\]](#)
- **HIV Perinatal Guidelines:** The Perinatal HIV Clinical Guidelines do not recommend treatment of HCV in pregnant people who have HIV due to the lack of safety data on the use of DAAs in pregnancy.[\[109\]](#) Instead, these individuals should be considered for HCV treatment with DAAs postpartum. Hence, pregnant people with HIV and HCV coinfection should have an HCV RNA checked postpartum to evaluate for spontaneous clearance of HCV prior to initiating DAA therapy.[\[108,109\]](#)
- **Immunizations for Hepatitis A and B:** Pregnant people with HIV and HCV coinfection should be screened for hepatitis A and B infection and receive vaccination during pregnancy if they are not already immune, and should be counseled about the signs and symptoms of liver toxicity.
- **Mode of Delivery:** For pregnant people with HIV and HCV coinfection, the mode of delivery should be based on standard obstetrical and HIV-related indications; specific intrapartum factors that may increase the risk of HIV transmission include emergent cesarean section, prolonged rupture of membranes (longer than 6 hours), and invasive fetal monitoring. These same intrapartum factors increase the risk of perinatal HCV transmission and thus should be avoided in pregnant people with HIV monoinfection, HCV monoinfection, or HIV and HCV coinfection.[\[4,10,106\]](#)
- **Breastfeeding:** Although HCV can be detected in breast milk, most studies have not shown an increase in transmission in breastfed infants.

Summary Points

- An estimated 15 to 30% percent of persons with HIV have HCV coinfection, with the highest rates among people with HIV who inject drugs and men with HIV who have sex with men.
- Compared with individuals who have HCV monoinfection, persons with HIV and HCV coinfection have accelerated rates of liver fibrosis that result in a more aggressive course of liver disease and higher rates of liver-related mortality.
- End-stage liver disease (ESLD), predominantly due to HCV infection, is now a leading cause of mortality in persons with HIV.
- All persons with HIV should be tested for HCV at entry to care with an HCV antibody test, and if positive, should have HCV RNA testing to confirm active infection.
- Individuals with HIV and HCV coinfection require an initial evaluation that includes a cirrhosis assessment.
- All persons with HIV and HCV coinfection should undergo treatment for HCV with the goal of achieving sustained virologic response and cure of HCV. Multiple studies have demonstrated comparable rates of sustained virologic response in persons with HCV monoinfection and HCV-HIV coinfection.
- Most people with HIV can receive the simplified HCV treatment approach with either an 8-week course of glecaprevir-pibrentasvir or a 12-week course with sofosbuvir-velpatasvir.
- All persons with HIV and HCV coinfection who are not eligible for the simplified HCV treatment strategy can be treated using the standard approach as outlined in the AASLD/IDSA treatment guidelines.
- In pregnant people with HCV monoinfection, the risk of perinatal HCV transmission is 4 to 7%, and coinfection with HIV increases the risk of perinatal HCV transmission by approximately 2-fold.
- Individuals with HCV and cirrhosis should undergo HCC screening every 6 months using abdominal ultrasound and serum alpha-fetoprotein.

Citations

1. World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization.
[[WHO](#)] -
2. Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. Hepatology. 2019;69:1020-31.
[[PubMed Abstract](#)] -
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
[[PubMed Abstract](#)] -
4. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Hepatitis C virus. Last Updated: January 18, 2023
[[HIV.gov](#)] -
5. Kim AY, Onofrey S, Church DR. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis. 2013;207 Suppl 1:S1-6.
[[PubMed Abstract](#)] -
6. Holtzman D, Asher AK, Schillie S. The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018. Am J Public Health. 2021;;e1-e7.
[[PubMed Abstract](#)] -
7. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2020.
[[CDC](#)] -
8. Crowell TA, Berry SA, Fleishman JA, et al. Impact of hepatitis coinfection on healthcare utilization among persons living with HIV. J Acquir Immune Defic Syndr. 2015;68:425-31.
[[PubMed Abstract](#)] -
9. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-7.
[[PubMed Abstract](#)] -
10. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-9.
[[PubMed Abstract](#)] -
11. Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10:297-302.
[[PubMed Abstract](#)] -
12. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis. 2013;26:66-72.
[[PubMed Abstract](#)] -
13. Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIV-infected men

enrolled in clinical trials. Clin Infect Dis. 2011;52:812-8.

[\[PubMed Abstract\]](#) -

14. Urbanus AT, Van De Laar TJ, Geskus R, et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS. 2014;28:781-90.
[\[PubMed Abstract\]](#) -
15. van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25:1083-91.
[\[PubMed Abstract\]](#) -
16. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS. 2011;6:451-8.
[\[PubMed Abstract\]](#) -
17. Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60:945-50.
[\[PubMed Abstract\]](#) -
18. Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68:585-93.
[\[PubMed Abstract\]](#) -
19. Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis. 2013;57:77-84.
[\[PubMed Abstract\]](#) -
20. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Unique patient populations: patients with HIV/HCV coinfection.
[\[AASLD/IDSA Hepatitis C Guidance\]](#) -
21. Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis. 2017;4:18-36.
[\[PubMed Abstract\]](#) -
22. Breskin A, Westreich D, Cole SR, et al. The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019;68:1152-9.
[\[PubMed Abstract\]](#) -
23. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011;6:478-82.
[\[PubMed Abstract\]](#) -
24. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198:1337-44.
[\[PubMed Abstract\]](#) -
25. Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369-79.
[\[PubMed Abstract\]](#) -

26. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology*. 2001;34:1193-9.
[[PubMed Abstract](#)] -
27. Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. *Clin Infect Dis*. 2013;56:1038-43.
[[PubMed Abstract](#)] -
28. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. *J Infect Dis*. 2008;198:683-6.
[[PubMed Abstract](#)] -
29. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. *Hepatology*. 2005;41:779-89.
[[PubMed Abstract](#)] -
30. Ragni MV, Egtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. *Liver Transpl*. 2005;11:1425-30.
[[PubMed Abstract](#)] -
31. de Ledinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. *J Viral Hepat*. 2008;15:427-33.
[[PubMed Abstract](#)] -
32. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *AIDS*. 2008;22:1979-91.
[[PubMed Abstract](#)] -
33. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. *JAMA*. 2002;288:199-206.
[[PubMed Abstract](#)] -
34. Rockstroh JK. Influence of viral hepatitis on HIV infection. *J Hepatol*. 2005;44:S25-7.
[[PubMed Abstract](#)] -
35. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. *AIDS*. 2006;20:1171-9.
[[PubMed Abstract](#)] -
36. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. *Clin Infect Dis*. 2005;41:713-20.
[[PubMed Abstract](#)] -
37. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. *JAMA*. 2014;312:353-61.
[[PubMed Abstract](#)] -
38. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. *AIDS*. 2004;18:2277-84.

[\[PubMed Abstract\]](#) -

39. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:S132-9.
[\[PubMed Abstract\]](#) -
40. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Considerations for antiretroviral use in patients with coinfections. hepatitis C virus/HIV coinfection. March 23, 2023.
[\[HIV.gov\]](#) -
41. Lo Re V Rd, Zeldow B, Kallan MJ, et al. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoevidemiol Drug Saf. 2017;26:1172-81.
[\[PubMed Abstract\]](#) -
42. Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology. 2015;62:1871-82.
[\[PubMed Abstract\]](#) -
43. van der Helm J, Gekus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013;144:751-760.e2.
[\[PubMed Abstract\]](#) -
44. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57:743-51.
[\[PubMed Abstract\]](#) -
45. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992-1002.
[\[PubMed Abstract\]](#) -
46. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-41.
[\[PubMed Abstract\]](#) -
47. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-8.
[\[PubMed Abstract\]](#) -
48. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. HCV testing and linkage to care.
[\[AASLD/IDSA Hepatitis C Guidance\]](#) -
49. Lambers FA, Prins M, Thomas X, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25:F21-7.
[\[PubMed Abstract\]](#) -
50. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
[\[AASLD/IDSA Hepatitis C Guidance\]](#) -

51. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62:362-5.
[[PubMed Abstract](#)] -
52. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55 Suppl 1:S43-8.
[[PubMed Abstract](#)] -
53. Majid AM, Gretch DR. Current and future hepatitis C virus diagnostic testing: problems and advancements. Microbes Infect. 2002;4:1227-36.
[[PubMed Abstract](#)] -
54. Richter SS. Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol. 2002;40:4407-12.
[[PubMed Abstract](#)] -
55. Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011;172:27-31.
[[PubMed Abstract](#)] -
56. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994-1002.
[[PubMed Abstract](#)] -
57. McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051-60.
[[PubMed Abstract](#)] -
58. Chamie G, Bonacini M, Bangsberg DR, et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis. 2007;44:577-83.
[[PubMed Abstract](#)] -
59. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
[[PubMed Abstract](#)] -
60. Labarga P, Soriano V, Caruz A, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS. 2011;25:761-6.
[[PubMed Abstract](#)] -
61. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-90.
[[PubMed Abstract](#)] -
62. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30.
[[PubMed Abstract](#)] -
63. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166:792-798.
[[PubMed Abstract](#)] -
64. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict

significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43:1317-25.

[\[PubMed Abstract\]](#) -

65. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. *J Clin Gastroenterol*. 2003;36:242-52.

[\[PubMed Abstract\]](#) -

66. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet*. 1997;349:825-32.

[\[PubMed Abstract\]](#) -

67. Safdar K, Schiff ER. Alcohol and hepatitis C. *Semin Liver Dis*. 2004;24:305-15.

[\[PubMed Abstract\]](#) -

68. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology*. 1998;28:805-9.

[\[PubMed Abstract\]](#) -

69. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. *MMWR Recomm Rep*. 1998 Oct 16;47:1-39.

[\[PubMed Abstract\]](#) -

70. Gorgos L. Sexual transmission of viral hepatitis. *Infect Dis Clin North Am*. 2013;27:811-36.

[\[PubMed Abstract\]](#) -

71. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. *J Infect Dis*. 2011;204:74-83.

[\[PubMed Abstract\]](#) -

72. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Initiation of antiretroviral therapy. December 18, 2019.

[\[HIV.gov\]](#) -

73. Wiktor SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection? *Lancet*. 2017;390:107-109.

[\[PubMed Abstract\]](#) -

74. Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. *Clin Infect Dis*. 2018;67:1010-17.

[\[PubMed Abstract\]](#) -

75. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *Lancet HIV*. 2015;2:e319-27.

[\[PubMed Abstract\]](#) -

76. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfecting with HIV-1. *N Engl J Med*. 2015;373:705-13.

[\[PubMed Abstract\]](#) -

77. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C.

When and in whom to initiate HCV therapy.

[\[AASLD/IDSA Hepatitis C Guidance\]](#) -

78. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. *Gastroenterology*. 2010;139:1593-601.
[\[PubMed Abstract\]](#) -
79. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med*. 2013;158:329-37.
[\[PubMed Abstract\]](#) -
80. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. *Clin Infect Dis*. 2015;61:730-40.
[\[PubMed Abstract\]](#) -
81. Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfecting with HIV. *J Acquir Immune Defic Syndr*. 2015;68:543-9.
[\[PubMed Abstract\]](#) -
82. Bichoupan K, Dieterich DT, Martel-Laferrrière V. HIV-hepatitis C virus co-infection in the era of direct-acting antivirals. *Curr HIV/AIDS Rep*. 2014;11:241-9.
[\[PubMed Abstract\]](#) -
83. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfecting with HCV genotype 1 and HIV-1: a phase 3 study. *Clin Infect Dis*. 2014;59:1579-87.
[\[PubMed Abstract\]](#) -
84. Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. *Clin Infect Dis*. 2017;64:1711-1720.
[\[PubMed Abstract\]](#) -
85. Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. *J Hepatol*. 2020;72:441-9.
[\[PubMed Abstract\]](#) -
86. Cornberg M, Ahumada A, Aghemo A, et al. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. *Adv Ther*. 2022;39:3146-58.
[\[PubMed Abstract\]](#) -
87. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfecting with HIV-1. *N Engl J Med*. 2015;373:714-25.
[\[PubMed Abstract\]](#) -
88. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis*. 2023 May 25;ciad319.
[\[PubMed Abstract\]](#) -

89. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Initial treatment of HCV infection.
[[AASLD/IDSA Hepatitis C Guidance](#)] -
90. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Retreatment of persons in whom prior therapy has failed.
[[AASLD/IDSA Hepatitis C Guidance](#)] -
91. Wyles D, Bräu N, Kottlil S, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017;65:6-12.
[[PubMed Abstract](#)] -
92. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-9.
[[PubMed Abstract](#)] -
93. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol. 2009;43:758-64.
[[PubMed Abstract](#)] -
94. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
[[PubMed Abstract](#)] -
95. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
[[PubMed Abstract](#)] -
96. Macías J, Berenguer J, Japón MA, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology. 2012;56:1261-70.
[[PubMed Abstract](#)] -
97. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916-22.
[[PubMed Abstract](#)] -
98. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453-63.
[[PubMed Abstract](#)] -
99. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53:1020-2.
[[PubMed Abstract](#)] -
100. Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr. 2015;68:456-62.
[[PubMed Abstract](#)] -

101. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology*. 2023;78:1922-65.
[[AASLD](#)] -
102. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey WD. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Am J Gastroenterol*. 2007;102:2086-102.
[[PubMed Abstract](#)] -
103. Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. *J Infect Dis*. 1997;176:414-20.
[[PubMed Abstract](#)] -
104. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. *J Med Virol*. 2009;81:836-43.
[[PubMed Abstract](#)] -
105. Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. *Clin Infect Dis*. 2007;44:1123-31.
[[PubMed Abstract](#)] -
106. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Special populations: HIV/hepatitis C virus coinfection. January 31, 2023.
[[HIV.gov](#)] -
107. European Paediatric Hepatitis C Virus Network. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. *J Infect Dis*. 2005;192:1872-9.
[[PubMed Abstract](#)] -
108. AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Unique patient populations: HCV in pregnancy.
[[AASLD/IDSA Guidance](#)] -
109. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Special Populations—Hepatitis C Virus/HIV Coinfection. December 29, 2020.
[[HIV.gov](#)] -

References

- AASLD/IDSA. HCV Guidance: Recommendations for testing, management, and treating hepatitis C. Simplified HCV Treatment for Treatment-Naive Adults Without Cirrhosis.
[[AASLD/IDSA Hepatitis C Guidance](#)] -
- Bosh KA, Coyle JR, Hansen V, et al. HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities. *Epidemiol Infect*. 2018;146:920-30.
[[PubMed Abstract](#)] -
- Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously

Treated HCV Infection. N Engl J Med. 2017;376:2134-46.

[\[PubMed Abstract\]](#) -

- Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-37.
[\[PubMed Abstract\]](#) -
- Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Pardo M, Carreño V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol. 2007;79:236-41.
[\[PubMed Abstract\]](#) -
- Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clin Infect Dis. 2020;71:e115-e124.
[\[PubMed Abstract\]](#) -
- Dore GJ, Feld JJ, Thompson A, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020;72:431-40.
[\[PubMed Abstract\]](#) -
- Harrington PR, Deming DJ, Komatsu TE, Naeger LK. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials. Clin Infect Dis. 2015;61:666-7.
[\[PubMed Abstract\]](#) -
- Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380.
[\[PubMed Abstract\]](#) -
- Lockart I, Matthews GV, Danta M. Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM. Curr Opin Infect Dis. 2019;32:31-7.
[\[PubMed Abstract\]](#) -
- Miro JM, Stock P, Teicher E, Duclos-Vallée JC, Terrault N, Rimola A. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update. J Hepatol. 2014;62:701-11.
[\[PubMed Abstract\]](#) -
- Ortiz V, Berenguer M, Rayón JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002;97:2408-14.
[\[PubMed Abstract\]](#) -
- Ostrow DE, Fox KJ, Chmiel JS, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 2002;16:775-80.
[\[PubMed Abstract\]](#) -
- Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285-93.
[\[PubMed Abstract\]](#) -
- Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet

Gastroenterol Hepatol. 2022;7:307-17.
[[PubMed Abstract](#)] -

Figures

Figure 1 Estimated Number of New Annual HCV Infections—United States, 2010 through 2020

Source: Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2020.




Figure 2 Progression to Cirrhosis in Persons with HIV and HCV Coinfection and HCV Monoinfection

This graph shows a retrospective analysis of 160 persons with HCV and the impact of HIV on the progression of HCV-related cirrhosis.

Source: Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-9.




Figure 3 Risk Factors for Liver-Related Deaths in Persons with HIV Infection

Source: Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-41.




Figure 4 HCV Testing Algorithm to Identify Current HCV Infection*

*For persons exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended. For immunocompromised persons, testing for HCV RNA can be considered.

¶To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, consider testing with another HCV antibody assay. Repeat HCV RNA testing if the person had HCV exposure within the past 6 months or has clinical evidence of HCV disease.

Source: Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62:362-5.




Figure 5 (Image Series) - Sustained Virologic Response 12 (SVR12) after HCV Treatment (Image Series) - Figure 5 (Image Series) - Sustained Virologic Response 12 (SVR12) after HCV Treatment

Image 5A: Sustained Virologic Response 12 (SVR12) after 8 Weeks of Treatment

This example shows virologic response to an 8-week HCV treatment course. As shown, a sustained virologic response 12 (SVR12) is defined as an undetectable HCV RNA level 12 weeks after stopping HCV therapy.

Illustration by David H. Spach, MD




Figure 5 (Image Series) - Sustained Virologic Response 12 (SVR12) after HCV Treatment
Image 5B: Sustained Virologic Response 12 (SVR12) after 12 Weeks of Treatment

This example shows virologic response to a 12-week HCV treatment course. As shown, a sustained virologic response 12 (SVR12) is defined as an undetectable HCV RNA level 12 weeks after stopping HCV therapy.

Illustration by David H. Spach, MD




Figure 6 (Image Series) - Virologic Monitoring HCV Treatment (Image Series) - Figure 6 (Image Series) - Virologic Monitoring HCV Treatment
Image 6A: Virologic Monitoring with 8-Week HCV Treatment Course

With this 8-week hepatitis C treatment course, the recommended virologic monitoring consists of baseline and 12-week posttreatment HCV RNA levels as shown in red dash circles.

Illustration by David H. Spach, MD




Figure 6 (Image Series) - Virologic Monitoring HCV Treatment
Image 6B: Virologic Monitoring with 12-Week HCV Treatment Course

With this 12-week hepatitis C treatment course, the recommended virologic monitoring consists of baseline and 12-week posttreatment HCV RNA levels as shown in red dash circles.

Illustration by David H. Spach, MD




Table 1. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Simplified HCV Treatment Regimens in People with HIV*

Treatment-Naïve Patients Without Cirrhosis (Any Genotype or No Pretreatment Genotype)

- Glecaprevir-pibrentasvir: three tablets daily for 8 weeks (AI), *or*
- Sofosbuvir-velpatasvir: one tablet daily for 12 weeks (AI)

Treatment-Naïve Patients with Compensated Cirrhosis (Recommendations Based on HCV Genotype)

HCV Genotypes 1, 2, 4, 6

Preferred Therapy

- Glecaprevir-pibrentasvir: three tablets daily for 8 weeks (**AIII**), *or*
- Sofosbuvir-velpatasvir: one tablet daily for 12 weeks (**AI**)

Alternative Therapy

- Glecaprevir-pibrentasvir: three tablets daily for 12 weeks (**CI**)

HCV Genotype 3

Preferred Therapy

- Glecaprevir-pibrentasvir: three tablets daily for 8 weeks (**AIII**)

Alternative Therapy

- Glecaprevir-pibrentasvir: three tablets daily for 12 weeks (**CI**), *or*
- Sofosbuvir-velpatasvir tablet: one daily, with or without ribavirin for 12 weeks pending results of NS5A resistance testing (**CI**)

Treatment of Acute HCV Infection

- Glecaprevir-pibrentasvir: three tablets daily for 8 weeks (**AII**), *or*
- Sofosbuvir-velpatasvir: one tablet daily for 12 weeks (**AII**)

*Each glecaprevir-pibrentasvir tablet contains glecaprevir (100 mg) and pibrentasvir (40 mg); each sofosbuvir-velpatasvir tablet contains sofosbuvir (400 mg) and velpatasvir (100 mg)

Recommendations for treatment after DAA failure are not provided; see the corresponding section in AASLD/IDSA HCV Treatment Guidance

Source:

- Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Hepatitis C virus. Last Updated: January 18, 2023 [[HIV.gov](https://www.hiv.gov)]

